No retraction, correction or concern found when last checked on Oct 18, 2026.

Unveiling the mechanisms and challenges of cancer drug resistance

Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha and 1 more

Cell Communication and Signaling · 2024 · Review · CC BY

doi:10.1186/s12964-023-01302-1

Read free

Abstract

Supplementary Information. The online version contains supplementary material available at 10.1186/s12964-023-01302-1.

References 400

1.
Nikolaou M, et al. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309-318.
Not in our library10.1007/s10585-018-9903-0
2.
Saha M, Sarkar A. Review on Multiple Facets of Drug Resistance: A Rising Challenge in the 21st Century. J Xenobiot. 2021;11(4):197-214.
Not in our library10.3390/jox11040013
3.
Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19(1):39-56.
Not in our library10.1038/s41573-019-0044-1
4.
Michaelis M, Wass MN, Cinatl J. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist. 2019;2(3):447-456.
Not in our library10.20517/cdr.2019.005
5.
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645-6653.
Not in our library10.1039/c8dt00838h
6.
Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015;24:S149-S153.
Not in our library10.1016/j.breast.2015.07.035
7.
Aramini B, et al. Dissecting tumor growth: The role of cancer stem cells in drug resistance and recurrence. Cancers (Basel). 2022;14(4):976.
Not in our library10.3390/cancers14040976
8.
Masoudi M, Gopalan V. Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. Cancer Stem Cells: Basic Concept and Therapeutic Implications. 2023;149-165.
Not in our library
9.
Overcoming cancer therapeutic bottleneck by drug repurposing · 2020
No notice
10.
DeRidder L, et al. The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022;352:840-860.
Not in our library10.1016/j.jconrel.2022.10.043
11.
Targeting strategies for bone diseases: signaling pathways and clinical studies · 2023
No notice
12.
Miglietta F, et al. Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism. Front Endocrinol (Lausanne). 2023;13:1085315.
Not in our library10.3389/fendo.2022.1085315
13.
The Different Mechanisms of Cancer Drug Resistance: A Brief Review · 2017
No notice
14.
Drug resistance and combating drug resistance in cancer · 2019
No notice
15.
Dzobo K, et al. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. OMICS. 2018;22(1):17-34.
Not in our library10.1089/omi.2017.0174
16.
Labrie M, et al. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323-339.
Not in our library10.1038/s41568-022-00454-5
17.
Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat. 2021;59:100796.
Not in our library10.1016/j.drup.2021.100796
18.
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited · 2023
No notice
19.
Dzobo K, et al. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells. 2020;9(8):1896.
Not in our library10.3390/cells9081896
20.
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer · 2017
No notice
21.
Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: Molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250:108522..
Not in our library10.1016/j.pharmthera.2023.108522
22.
Yang Q, et al. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications. Adv Sci (Weinh). 2022;9(34):e2201609.
Not in our library10.1002/advs.202201609
23.
Namee NM, O'Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. 2018;1870(2):123-136.
Not in our library10.1016/j.bbcan.2018.07.003
24.
Wu S. Fu L, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):1-13.
Not in our library10.1186/s12943-018-0775-3
25.
Roviello G, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372(2):187-191.
Not in our library10.1016/j.canlet.2016.01.014
26.
Martin SK, et al. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol. 2015;9(3):628-639.
Not in our library10.1016/j.molonc.2014.10.014
27.
Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019;37(3):288-295.
Not in our library10.5534/wjmh.180040
28.
Asano Y, et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer. 2016;114(1):14-20.
Not in our library10.1038/bjc.2015.434
29.
Barton VN, et al. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Res. 2017;77(13):3455-3466.
Not in our library10.1158/0008-5472.can-16-3240
30.
Niikura N, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480-487.
Not in our library10.1093/annonc/mdv611
31.
Tolaney SM, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763-775.
Not in our library10.1016/s1470-2045(20)30112-1
32.
Calabrò L, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301-309.
Not in our library10.1016/s2213-2600(15)00092-2
33.
Calabrò L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-1111.
Not in our library10.1016/s1470-2045(13)70381-4
34.
Noguchi T, et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune EscapeThe Role of Tumor versus Host PD-L1 in Tumor Immune Escape. Cancer Immunol Res. 2017;5(2):106-117.
Not in our library10.1158/2326-6066.cir-16-0391
35.
Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895-904.
Not in our library10.1084/jem.20160801
36.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
Not in our library10.1126/science.aar4060
37.
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · 2023
No notice
38.
Prasad B, et al. Exploration of space to achieve scientific breakthroughs. Biotechnol Adv. 2020;43:107572.
Not in our library10.1016/j.biotechadv.2020.107572
39.
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discovery. 2023;22(3):213-234.
Not in our library10.1038/s41573-022-00615-z
40.
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy · 2019
No notice

All 400 references

Cited by papers we hold 1

Invasion and metastasis in cancer: molecular insights and therapeutic targets · 2025
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.